Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 150 of 5804
-
New combo aims to spare surgery for certain cancer patients
Disease control Recruiting nowThis study intends to explore the role of PD1/PDL1 antibody with selective combination of Sintilimab, IBI310 and Lenvatinib in organ preservation in non-metastatic dMMR/MSI-H gastric or colon cancers with mismatch repair deficiency or high microsatellite instability
Phase: PHASE2 • Sponsor: Peking University • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Can community conversations curb suicide in rural alaska?
Disease control OngoingThis participatory, pragmatic efficacy-implementation trial evaluates the impact of Promoting Community Conversations About Research to End Suicide (PC CARES) to evaluate Learning Circle (LC) participant outcomes (AIM#1), community-wide diffusion effects, and efficacy by tracking…
Phase: NA • Sponsor: University of Michigan • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New hope for stiff lungs? drug trial targets scarring from autoimmune disease
Disease control Recruiting nowInterstitial lung disease (ILD) is a lung condition resulting in inflammation and stiffening of the lung, often associated with connective tissue diseases (CTDs). ILD causes reduction in lung volume, shortness of breath, cough and fatigue therefore has high impact on quality of l…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New hope for pancreatic cancer: four-drug combo tested in phase 2 trial
Disease control Recruiting nowPancreatic cancer is a kind of digestive system tumor with high malignant degree and poor prognosis. Most patients with pancreatic cancer are locally advanced or have distant metastases at the time of diagnosis, so it is extremely important to find effective drugs to control tumo…
Phase: PHASE2 • Sponsor: Liu Xiufeng • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Magic mushroom compound may quiet the depressed Brain's endless Self-Criticism
Symptom relief Recruiting nowThis open-label functional Magnetic Resonance Imaging (fMRI) study will assess the effects of a single dose of psilocybin on rumination and the neural correlates of rumination in individuals with major depressive disorder.
Phase: PHASE3 • Sponsor: Sharmin Ghaznavi • Aim: Symptom relief
Last updated Jul 19, 2026 00:00 UTC
-
Cholera vaccine ring strategy tested in bangladesh hotspots
Prevention Recruiting nowTo evaluate the effectiveness of the CATI approach among household contacts in the reduction of cumulative incidence of cholera and explore the genome analysis and immune response of V. cholerae antigen from different hotspots in Dhaka city, cholera cases will be enrolled by rapi…
Phase: NA • Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh • Aim: Prevention
Last updated Jul 08, 2026 00:00 UTC
-
Could a simple tablet test and AI catch dementia years earlier?
Diagnosis ENROLLING_BY_INVITATIONThe goal of this observational trial is to leverage the electronic Self-Administered Gerocognitive Examination (eSAGE), a variety of metadata (a set of data that describes and gives information about other data) collected during eSAGE testing, electronic health records (EHR) info…
Sponsor: Douglas Scharre • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
New combo aims to boost CAR-T power against stubborn lymphoma
Disease control Recruiting nowThis is a phase 2, open-label, randomized, multicenter clinical trial in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) who meet the criteria for standard-of-care FDA label for CD19 CAR T-cell therapy with brexucabtagene autoleucel (brexu-cel).
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Robots vs. therapists: a head-to-head trial for stroke recovery
Disease control Recruiting nowRehabilitation after stroke often employs Robot and Allied Digital Technologies (RADTs), yet evidence on their effectiveness remains inconclusive due to study heterogeneity and limited sample sizes. This multicentre randomized controlled pragmatic trial aims at comprehensively a…
Phase: NA • Sponsor: Fondazione Don Carlo Gnocchi ETS • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New hope for bile duct cancer: targeted therapy duo takes on standard chemo
Disease control Recruiting nowThe purpose of this study is to measure the efficacy and safety of T-DXd with rilvegostomig or T-DXd monotherapy compared with gemcitabine plus cisplatin and durvalumab in patients with advanced treatment naïve HER2-expressing BTC.
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New drug combo aims to control tough leukemia
Disease control Recruiting nowTo learn if the combination of blinatumomab and asciminib can help to control Ph+ ALL.
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New combo therapy aims to spare lymph nodes and boost rectal cancer outcomes
Disease control OngoingThis is a randomized, prospective, multicenter, open-label, Phase III clinical trial to evaluate node-sparing modified short-course radiation (Radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes) combined with CAPOX and PD-1 Inhibitor (Tis…
Phase: PHASE3 • Sponsor: Sir Run Run Shaw Hospital • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New cord blood transplant method aims to beat high-risk blood cancers
Disease control Recruiting nowThis phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide, fludarabine, and total-body irradiation (TBI) works in treating patients with hematologic diseases. Giving chemotherapy, such as cyclophosphamide, fludarabine and thiote…
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New hope for rare cancers: immunotherapy drug dostarlimab takes on chemo in phase 2 trial
Disease control Recruiting nowThe goal of this open-label randomized, multicenter, comparative phase II trial is to evaluate the efficacy of the immunotherapy, dostarlimab, as first-line treatment for deficient mismatch repair (dMMR)/microsatellite instability (MSI) non-resectable metastatic or locally advanc…
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New hope for chronic hives: barzolvolimab in Late-Stage trial
Disease control OngoingThe purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.
Phase: PHASE3 • Sponsor: Celldex Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New trial aims to find best treatment for older lung cancer patients
Disease control Recruiting nowThis phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system atta…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can a new drug calm the storm of bipolar mania?
Disease control CompletedThis is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with or without psychotic symptoms, according to criteri…
Phase: PHASE3 • Sponsor: Intra-Cellular Therapies, Inc. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New immune therapy shows promise for Tough-to-Treat lymphoma
Disease control Recruiting nowThe goal of this clinical trial is to learn if a new type of chimeric antigen receptor (CAR) T-cell therapy called WZTL-002 is effective and safe for the treatment large B-cell lymphomas (LBCL) that have not responded to or have come back after standard chemotherapy. The main que…
Phase: PHASE2 • Sponsor: Malaghan Institute of Medical Research • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
One-Time gene therapy could change gaucher treatment forever
Disease control Recruiting nowGaucher disease (GD) is caused by mutations in the GBA1 gene, which leads to a lack or reduction of GCase activity. The consequences of this deficiency are generally attributed to the accumulation of the GCase substrate, Glucosylceramide (GlcCer), in macrophages in the liver, spl…
Phase: PHASE1, PHASE2 • Sponsor: Lingyi Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
Chilled saline infused directly into brain during stroke treatment may limit damage
Disease control CompletedThis is a multicenter, randomized, controlled, subject- and assessor-blinded clinical trial. The research objective is to evaluate the safety and efficacy of selective intra-arterial cooling infusion combined with endovascular therapy in the treatment of acute anterior circulatio…
Phase: NA • Sponsor: Beijing Shijitan Hospital, Capital Medical University • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC